Mechanisms of Hormone Action¶
Chapter 389 | Part 12: Endocrinology and Metabolism · Part 12 – Endocrinology & Metabolism · Chapter 389
Key Clinical Points¶
- Immunoassays are the primary diagnostic tool in endocrinology, providing sensitive, specific, and quantitative determination of steady-state and dynamic hormone concentrations.
- Hormones are classified into five major types: (1) amino acid derivatives (e.g., dopamine, catecholamine, thyroid hormone), (2) small neuropeptides (e.g., GnRH, TRH, somatostatin, vasopressin), (3) large proteins (e.g., insulin, LH, PTH), (4) steroid hormones (e.g., cortisol, estrogen), and (5) vitamin derivatives (e.g., retinoids, vitamin D).
- Membrane receptors primarily bind peptide hormones and catecholamines; nuclear receptors bind small molecules (steroids, vitamin D) that diffuse across the cell membrane.
- G protein–coupled receptors (GPCRs) signal via Gα subunits (Gs, Gi, Gq) to activate effectors like adenylate cyclase, phospholipase C, or ion channels.
- Tyrosine kinase receptors (e.g., insulin, IGF-I) undergo autophosphorylation and activate intracellular adaptor proteins (IRS) and kinases (Raf-Ras-MAPK, Akt).
- Nuclear receptors bind DNA as dimers (homodimers or heterodimers with RXR) and regulate transcription via co-repressors or co-activators.
- Hormone binding proteins (e.g., TBG, SHBG, IGFBPs) provide a reservoir, restrict access to certain sites, and modulate free hormone concentrations.
- Genetic mutations in receptors can cause resistance syndromes (e.g., androgen insensitivity) or constitutive activation (e.g., McCune-Albright syndrome).
- Dynamic testing (suppression or stimulation) is used when basal hormone levels overlap with normal ranges to distinguish primary from secondary disorders.
- Gα mutations that eliminate GTPase activity result in constitutive activation of receptor signaling pathways, mimicking chronic hormone stimulation (e.g., Gαs mutations causing GH-producing adenomas).
DEFINITION & OVERVIEW¶
• Endocrine System: Regulates growth, metabolism, homeostasis, and reproduction. Hormones serve to coordinate physiologic responses to external or internal cues.
• Hormone Measurement and Endocrine Testing: • Immunoassays: Primary diagnostic tool; provides sensitive, specific, and quantitative determination of steady-state and dynamic changes. • Methodology: Often utilize two antibodies (capture and signal) to increase binding affinity/specificity. Can distinguish structurally related proteins (e.g., PTH from PTHrP). • Sensitivity: Detect concentrations in the picomolar to nanomolar range. • Alternative Techniques: Mass spectroscopy (multi-analyte detection), chromatography, and enzymatic methods; bioassays are now used rarely. • Urinary Determinations: Useful for integrated assessment of production/metabolism over 24h. • Urinary Controls: Simultaneous measurement of creatinine provides an internal control for collection adequacy and allows normalization of results. • Specific Urinary Markers: 24-h urine-free cortisol (reflects unbound hormone), 17-hydroxycorticosteroids, 17-ketosteroids, vanillylmandelic acid (VMA), metanephrine, catecholamines, 5-hydroxyindoleacetic acid (5-HIAA), and calcium.
EPIDEMIOLOGY¶
• Prevalence: Many endocrine disorders are prevalent in the adult population. • Clinical Impact: High prevalence justifies vigilance during routine physical examinations; targeted screening for high-risk populations. • Genetic Patterns: Specific genetic disorders (e.g., McCune-Albright syndrome, MEN2) have specific inheritance patterns and prevalence rates associated with germline or somatic mutations.
ETIOLOGY & PATHOPHYYSICOLOGY¶
Hormone Classification and Receptor Interaction¶
• Five Major Hormone Types: 1. Amino acid derivatives (e.g., dopamine, catecholamine, thyroid hormone) 2. Small neuropeptides (e.g., GnRH, TRH, somatostatin, vasopressin) 3. Large proteins (e.g., insulin, LH, PTH) 4. Steroid hormones (e.g., cortisol, estrogen) - synthesized from cholesterol 5. Vitamin derivatives (e.g., retinoids, vitamin D)
• Receptor Binding Rules: • Membrane receptors: Bind peptide hormones and catecholamines. • Nuclear receptors: Bind lipid-soluble molecules (steroids, thyroid hormone, vitamin D, retinoic acid).
• Cross-Talk & Specificity: • IGF System: High concentrations of IGF2 can bind to both insulin and IGF1 receptors; high insulin also binds the IGF1 receptor. • PTH/PTHrP: Both hormones bind the PTH1R receptor in bone and kidney. Differentiation requires specific assays for PTH vs. PTHrP.
• Nuclear Receptor Subtypes: • Type 1: Glucocorticoid, mineralocorticoid, androgen, estrogen, and progesterone receptors (bind steroids). • Type 2: Thyroid hormone, vitamin D, retinoic acid, and peroxisome proliferator activated receptor (PPAR) (bind thyroid hormone, vitamin D, retinoic acid, or lipid derivatives).
• Specificity Exceptions: • Mineralocorticoid Receptor: Also binds glucocorticoids; high cortisol levels (e.g., Cushing's syndrome) can saturate the 11β-hydroxysteroid dehydrogenase enzyme in renal tubular cells, leading to sodium retention and potassium wasting. • Estrogen Receptor: Less specific; binds various compounds including "environmental estrogens" (resveratrol, octylphenol). This allows for the development of antagonists (e.g., tamoxifen) and selective estrogen response modulators (SERMs) like raloxifene.
Hormone Synthesis and Processing¶
• Peptide Hormone Pathway: Gene expression → mRNA → protein → posttranslational processing → intracellular sorting → membrane integration or secretion. • Prohormones: Many are produced as inactive precursors (e.g., POMC → ACTH; proglucagon → glucagon, GLP1; proinsulin → insulin; pro-PTH → PTH). • Steroid/Thyroid Processing: Steroids require multiple regulated enzymatic steps from cholesterol; thyroid hormones undergo conversion (T4 → T3). • Regulation Mechanisms: • Nuclear Receptors: TSH genes are repressed directly by thyroid hormones acting through the TR. • Steroidogenesis: Requires specific transcription factors, such as steroidogenic factor 1 (SF1), which acts as a master regulator in response to signals from LH or ACTH. • Translation: Insulin biosynthesis is regulated primarily at the translational and secretory levels in response to glucose or amino acids.
Hormone Secretion, Transport, and Degradation¶
• Secretory Dynamics: • Peptide Hormones: Stored in granules; released via neural/chemical signals (e.g., GnRH, insulin, GH). • Steroid Hormones: Diffuse into circulation as they are synthesized; secretion rates align with synthesis rates. • Half-life Variations: • TSH: ≈ 7 days (requires >1 month to reach steady state; single daily doses sufficient). • T3: ≈ 1 day (rapid turnover, requires multiple daily doses). • Dexamethasone: Longer half-life leads to greater suppression of the HPA axis.
• Binding Proteins & Function: • Examples: TBG, SHBG, IGFBPs. • Functions: Provide a reservoir, restrict access to certain sites, and modulate free hormone concentrations. Most abnormalities have little clinical consequence unless they affect the "free" fraction or specific pathways (e.g., mineralocorticoid receptor saturation).
CLINICAL FEATURES¶
Clinical Presentation of Receptor Mutations¶
• Loss-of-Function (Recessive): Often resemble glandular failure (e.g., LH-R, TSH-R mutations). • Gain-of-Function (Dominant/Somatic): Result in constitutive activation. • Specific Syndromes: • Androgen Insensitivity (AIS): XY individuals with female phenotype and high testosterone. • McCune-Albright Syndrome: Mosaic Gα mutations → constitutive activation of PTH, MSH, TSH, and GHRH pathways. • Gα Mutations: Mutations eliminating GTPase activity result in constitutive signaling (e.g., Gαs → GH-producing adenomas). • Specific Receptor Disorders (from Table 2): • LH: Leydig cell hypoplasia, Primary amenorrhea, Familial male precocious puberty, Leydig cell adenoma. • TSH: Congenital hypothyroidism, TSH resistance, Nonautoimmune familial hyperthyroidism, Hyperfunctioning thyroid adenoma. • Kisspeptin: Hypogonadotropic hypogonadism, Precocious puberty. • TRH: Central hypothyroidism, GH deficiency. • PTH: Blomstrand chondrodysplasia, Jansen metaphyseal chondrodysplasia, Familial hypocaluric hypercalcemia, Neonatal severe hyperparathyroidism, Familial hypocalcemic hypercalciuria. • ARV2: Nephrogenic diabetes insipidus, Nephrogenic SIADH, Familial ACTH resistance, ACTH-independent Cushing syndrome. • Melanocortin 4: Severe obesity.
DIFFERENTIAL DIAGNOSIS¶
• Primary vs. Secondary Distinction: Determined by comparing basal hormone levels with dynamic testing (suppression or stimulation) when values overlap. • Calcium/PTH Differentiation: High Ca + High PTH → Hyperparathyroidism; High Ca + Suppressed PTH → Malignancy or granulomatous disease (distinguished via specific assays for PTH vs. PTHrP).
INVESTIGATIONS & DIAGNOSIS¶
Hormone and Receptor Families¶
• GPCRs: LH, FSH, TSH, β-adrenergic, Glucagon, PTH, PTHrP, ACTH, MSH, GHRH, CRH, Somatostatin, α-adrenergic, TRH, GnRH. • Tyrosine Kinase: GH, PRL. • Nuclear Receptors: AR, ER, GR, PR, VDR, TR, RAR, PPAR.
MANAGEMENT & TREATMENT¶
• Pharmacological Strategy for Estrogen Receptor: 1. Identify specific receptor interactions (e.g., ER's ability to bind various compounds). 2. Utilize targeted agents: - Antagonists: e.g., tamoxifen (to block activation by environmental estrogens). - SERMs: e.g., raloxifene (to create distinct conformations and alter interaction with transcription machinery).
KEY PEARLS & CLINICAL TRAPS¶
• Immunoassay Superiority: Gold standard for sensitivity, specificity, and quantification of both steady-state and dynamic changes. • Gα Mutation Impact: Mutations eliminating GTPase activity lead to constitutive activation (e.g., Gαs → GH-producing adenomas). • Binding Protein Nuance: Most binding protein abnormalities have little clinical consequence; however, they are essential for maintaining the reservoir and modulating free hormone levels. • Thyroid Hormone Half-life: TSH (7 days) vs. T3 (1 day) dictates dosing frequency and time to reach steady state.
Reference Tables¶
TABLE 389-1 Examples of Membrane Receptor Families and Signaling Pathways RECEPTORS G Protein–Coupled…¶
Harrison's 22e, p.2981
| RECEPTORS | EFFECTORS | SIGNALING PATHWAYS |
|---|---|---|
| G Protein–Coupled Seven-Transmembrane Receptor (GPCR) | ||
| LH, FSH, TSH, β-adrenergic |
Gα, adenylate s cyclase |
Stimulation of cyclic AMP production, protein kinase A |
| Glucagon, PTH, PTHrP, ACTH, MSH, GHRH, CRH |
Ca2+ channels | Calmodulin, Ca2+-dependent kinases |
| Somatostatin, α-adrenergic |
Gα i |
Inhibition of cyclic AMP production Activation of K+, Ca2+ channels |
| TRH, GnRH | G, G q 11 |
Phospholipase C, diacyl- glycerol, IP, protein kinase 3 C, voltage-dependent Ca2+ channels |
| Receptor Tyrosine Kinase | ||
| Cytokine Receptor–Linked Kinase | ||
| GH, PRL | JAK, tyrosine kinases | STAT, MAP kinase, PI 3-kinase, IRS-1 |
| Serine Kinase |
TABLE 389-2 Genetic Causes of G protein Receptor Disorders RECEPTOR LH¶
Harrison's 22e, p.2985
| RECEPTOR | DISORDER | GENETICS |
|---|---|---|
| LH | Leydig cell hypoplasia (male) Primary amenorrhea, resistance to LH (female) Familial male precocious puberty (male) Leydig cell adenoma, precocious puberty (male) |
AR, inactivating AR, inactivating AD, activating Sporadic, activating |
| Hypergonadotropic ovarian failure (female) Hypospermia (male) Ovarian hyperstimulation (female) |
||
| TSH | Congenital hypothyroidism, TSH resistance Nonautoimmune familial hyperthyroidism Hyperfunctioning thyroid adenoma |
AR, AD, inactivating AD, activating Sporadic, activating |
| Hypogonadotropic hypogonadism | ||
| Kisspeptin | Hypogonadotropic hypogonadism Precocious puberty |
AR, inactivating AD, activating |
| Precocious puberty | ||
| TRH | Central hypothyroidism | AR, inactivating |
| GH deficiency | ||
| PTH | Blomstrand chondrodysplasia Jansen metaphyseal chondrodysplasia |
AR, inactivating AD, activating |
| Familial hypocalciuric hypercalcemia Neonatal severe hyperparathyroidism Familial hypocalcemic hypercalciura |
||
| Arginine vasopressin receptor 2 |
Nephrogenic diabetes insipidus Nephrogenic SIADH |
XL, inactivating XL, activating |
| Familial ACTH resistance ACTH-independent Cushing syndrome |
||
| Melanocortin 4 | Severe obesity | Codominant, inactivating |